钆布醇增强心脏磁共振检测冠状动脉疾病
两项设计几乎相同的国际III期临床试验GadaCAD1和GadaCAD2评估钆布醇增强心脏磁共振(CMR)检测冠状动脉疾病(CAD)的诊断准确性。固定效应荟萃分析(n=764)显示,以QCA≥70%狭窄定义CAD(患病率27.8%),CMR灵敏度78.9%、特异度86.8%、AUC 0.871。结论支持FDA批准钆布醇增强CMR(0.1 mmol/kg)用于评估成人已知或疑似CAD的心肌灌注和LGE。
要点
- 钆布醇增强CMR检测QCA≥70%狭窄的灵敏度78.9%、特异度86.8%。
- 多支血管CAD的灵敏度和特异度分别为87.4%和73.0%。
- 结果支持FDA批准钆布醇增强CMR(0.1 mmol/kg)用于CAD评估。
核心结论
- 血管扩张剂负荷和静息心肌灌注CMR及LGE成像在两项III期临床试验中对CAD具有高诊断准确性。
- 这些发现支持FDA批准钆布醇增强CMR(0.1 mmol/kg)用于评估成人已知或疑似CAD的心肌灌注和LGE。
研究设计与样本
- 两项国际、单 vendor、设计几乎相同的III期临床试验GadaCAD1(n=376)和GadaCAD2(n=388)汇总为固定效应荟萃分析(n=764)。
主要发现
- CAD患病率27.8%(定义为QCA≥70%狭窄)。
- 检测QCA≥70%狭窄:CMR灵敏度78.9%,特异度86.8%,AUC 0.871。
- 多支血管CAD:灵敏度87.4%,特异度73.0%。
- 检测QCA≥50%狭窄:灵敏度64.6%,特异度86.6%。
- 检测CAD的最佳阈值:GadaCAD1为QCA≥67%狭窄,GadaCAD2为QCA≥63%狭窄。
关键数值与推荐
- CMR检测QCA≥70%狭窄的灵敏度78.9%、特异度86.8%、AUC 0.871。
- CMR检测多支血管CAD的灵敏度87.4%、特异度73.0%。
- 检测QCA≥50%狭窄的灵敏度64.6%、特异度86.6%。
临床怎么用
- 钆布醇增强CMR(0.1 mmol/kg)可用于成人已知或疑似CAD的心肌灌注和LGE评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gadolinium-based contrast agents were not approved in the United States for detecting coronary artery disease (CAD) prior to the current studies. OBJECTIVES: The purpose of this study was to determine the sensitivity and specificity of gadobutrol for detection of CAD by assessing myocardial perfusion and late gadolinium enhancement (LGE) imaging. METHODS: Two international, single-vendor, phase 3 clinical trials of near identical design, "GadaCAD1" and "GadaCAD2," were performed. Cardiovascular magnetic resonance (CMR) included gadobutrol-enhanced first-pass vasodilator stress and rest perfusion followed by LGE imaging. CAD was defined by quantitative coronary angiography (QCA) but computed tomography coronary angiography could exclude significant CAD. RESULTS: Because the design and results for GadaCAD1 (n = 376) and GadaCAD2 (n = 388) were very similar, results were summarized as a fixed-effect meta-analysis (n = 764). The prevalence of CAD was 27.8% defined by a ≥70% QCA stenosis. For detection of a ≥70% QCA stenosis, the sensitivity of CMR was 78.9%, specificity was 86.8%, and area under the curve was 0.871. The sensitivity and specificity for multivessel CAD was 87.4% and 73.0%. For detection of a 50% QCA stenosis, sensitivity was 64.6% and specificity was 86.6%. The optimal threshold for detecting CAD was a ≥67% QCA stenosis in GadaCAD1 and ≥63% QCA stenosis in GadaCAD2. CONCLUSIONS: Vasodilator stress and rest myocardial perfusion CMR and LGE imaging had high diagnostic accuracy for CAD in 2 phase 3 clinical trials. These findings supported the U.S. Food and Drug Administration approval of gadobutrol-enhanced CMR (0.1 mmol/kg) to assess myocardial perfusion and LGE in adult patients with known or suspected CAD.
引用
- Arai AE, Schulz-Menger J, Berman D, et al. Gadobutrol-Enhanced Cardiac Magnetic Resonance Imaging for Detection of Coronary Artery Disease. J Am Coll Cardiol. 2020. PMID: 32972530. doi:10.1016/j.jacc.2020.07.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。